Joseph Breese - Sabin Vaccine Institute

More documents

Recommendations

Info

Meta-analyses of influenza vaccine LAIV efficacy/effectiveness in children Reference No. studies / subjects Age range Study types Summary VE % Rhorer (2009) 9 / 27,000 6-71 m RCTs 72 Negri (2005) 6 / 4400 6 m–18 y RCT / Obs 80 (53-91) Jefferson (2008) 34 < 16 y RCT / Obs. 82 (71-89) Osterholm (2012) TIV 10 6m - 7 y RCT 83 (69-91) Jefferson (2008) 34 < 16 y RCT /Obs 59 (41-71) Negri (2005) 6 /2300 6 m–18 y RCT / Obs 65 (45-77)
<strong>Vaccine</strong> effectiveness: special populations: Elderly persons – Lower VE measured in elderly populations – Studies difficult because • RCTs rare because flu vaccine long-recommended in this group • Confounding in observational studies – Even so, well-done RCT and observational studies able to measure significant reductions in disease • Only RCT of influenza vaccine VE in the elderly (Govaert et al. JAMA. 1994;272:1661-1665) • Subjects: aged ≥60, generally healthy • VE overall = 50% (CI: 39 - 65) • 60-69 years: 57% (CI: 33 - 72) • >70: 23% (CI: -51 - 61)
Page 1 and 2: Overview of seasonal Influenza Vacc
Page 3 and 4: Seasonal Influenza Vaccines INFLUEN
Page 5 and 6: Clinical trials of inactivated vacc
Page 7 and 8: Influenza Vaccines - overview • T
Page 9 and 10: Influenza vaccines: types “Standa
Page 11 and 12: Influenza vaccines: types High-dose
Page 13 and 14: Seasonal Influenza Vaccines VACCINE
Page 15: Influenza Vaccine efficacy if IIV i
Page 19 and 20: Indirect effects of influenza vacci
Page 21 and 22: Estimates number of medically-atten
Page 23 and 24: Influenza vaccines have been part o
Page 25 and 26: Seasonal Influenza Vaccines CHALLEN
Page 27 and 28: Gaps • Most partners need educati
Page 29: THANK YOU

Joseph Breese - Sabin Vaccine Institute

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?